Sánchez-Berná Isabel, Santiago-Díaz Carlos, Jiménez-Alonso Juan
Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, España.
Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, España.
Med Clin (Barc). 2015 Jan 20;144(2):88-91. doi: 10.1016/j.medcli.2014.01.014. Epub 2014 Mar 15.
Autoimmune diseases are a cluster of disorders characterized by a failure of the immune tolerance and a hyperactivation of the immune system that leads to a chronic inflammation state and the damage of several organs. The medications currently used to treat these diseases usually consist of immunosuppressive drugs that have significant systemic toxic effects and are associated with an increased risk of opportunistic infections. Recently, several studies have demonstrated that mesenchymal stem cells have immunomodulatory properties, a feature that make them candidates to be used in the treatment of autoimmune diseases. In the present study, we reviewed the role of this therapy in the treatment of systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, Crohn's disease and multiple sclerosis, as well as the potential risks associated with its use.
自身免疫性疾病是一组以免疫耐受失败和免疫系统过度激活为特征的疾病,这会导致慢性炎症状态以及多个器官的损伤。目前用于治疗这些疾病的药物通常由具有显著全身毒性作用且与机会性感染风险增加相关的免疫抑制药物组成。最近,多项研究表明间充质干细胞具有免疫调节特性,这一特性使其成为可用于治疗自身免疫性疾病的候选者。在本研究中,我们综述了这种疗法在治疗系统性红斑狼疮、干燥综合征、系统性硬化症、克罗恩病和多发性硬化症中的作用,以及与其使用相关的潜在风险。